The research and development of new medicines is a lengthy and sequential process that spans more than a decade, culminating in regulatory approval based on evidence of quality, safety, and efficacy from clinical trial data. In Thailand, it takes nearly an additional decade for new medicines to be included in the Thailand National List of Essential

Non-communicable diseases (NCDs) are often called “silent killers”, but there is nothing silent about their impact. They remain one of the hardest public health battles to win. According to the World Health Organisation (WHO), they cause 43 million deaths worldwide and account for 75% of non-pandemi

Background & RationaleNon-communicable diseases (NCDs) are the leading cause of death worldwide, responsible for 43 million deaths annually and accounting for 75% of all non-pandemic-related mortality globally [1]. Cardiovascular disease, diabetes, cancer, and chronic respiratory conditions drive this burden, yet most health systems remain orie

The development of health and medical innovation is a key national strategy for Thailand under the 13th National Economic and Social Development Plan, which aims to position the country as a high-value medical and wellness hub while reducing dependence on imported medical technologies. The Thai Innovation List was established to promote the commerc

This project evaluates Thailand’s maternal acellular pertussis vaccination policy after its inclusion in the Universal Health Coverage benefit package. Although the vaccine is available free of charge, uptake among pregnant women remained low in 2024. The study combines health economic modelling, budget impact analysis, and quantitative and quali

The development of medical innovation is one of Thailand’s key strategic priorities, as outlined in the 13th National Economic and Social Development Plan (2023–2027), with Milestone 4 positioning Thailand as a hub for high-value medical and healthcare services. However, Thailand’s research and development in medical technologies and health i

The development of medical innovation is one of Thailand’s key strategic priorities as outlined in the 13th National Economic and Social Development Plan (2023–2027). Milestone 4 identifies Thailand’s ambition to become a high-value medical and wellness hub, with the goal of strengthening the country’s capacity to generate economic value fr

The Thai Innovation List was established in 2015 to compile products and services developed through Thailand’s scientific and technological knowledge and research capacity. The initiative was designed to support and promote the utilization of Thai innovations for economic development and commercialization. Medical innovations account for approxim

The development of medical innovation is one of Thailand’s key strategic priorities as outlined in the 13th National Economic and Social Development Plan (2023–2027). Milestone 4 identifies Thailand’s ambition to become a high-value medical and wellness hub, with the goal of strengthening the country’s capacity to generate economic value fr

This study marks Thailand’s first application of Distributional Cost-Effectiveness Analysis (DCEA), demonstrating that the concept of “equity” can be incorporated into economic evaluation. The analysis examines dialysis options, namely peritoneal dialysis (PD) and hemodialysis (HD), for patients